Apoa5 Antibody
Description
Definition and Biological Relevance
ApoA5 antibodies are immunoreagents designed to bind specifically to the ApoA5 protein, a liver-derived apolipoprotein that modulates plasma triglyceride levels by influencing lipoprotein lipase (LPL) activity and very-low-density lipoprotein (VLDL) production . These antibodies are pivotal for:
-
Protein detection: Identifying ApoA5 in tissues (e.g., liver, small intestine) and plasma fractions .
-
Mechanistic studies: Elucidating ApoA5’s role in triglyceride homeostasis and its interaction with regulatory complexes like ANGPTL3/8 .
-
Disease research: Investigating hypertriglyceridemia and metabolic syndrome linked to ApoA5 dysfunction .
Key Antibody Characteristics and Applications
ApoA5 antibodies vary in host species, clonality, and applications. Below is a comparison of notable commercial and research-grade ApoA5 antibodies:
-
Western blot (WB): Detects ApoA5 at ~41 kDa (precursor) and 39 kDa (mature form) .
-
Immunoprecipitation (IP): Isolates ApoA5 complexes for interaction studies .
-
Immunofluorescence: Localizes ApoA5 in hepatocytes and lipid droplets .
Role in Triglyceride Regulation
-
ApoA5 antibodies confirmed that hepatic ApoA5 deficiency increases plasma triglycerides by reducing LPL activity and promoting lipid droplet accumulation in hepatocytes .
-
Studies using CT-APOA5 pAb demonstrated that C-terminal sequences of ApoA5 are essential for suppressing ANGPTL3/8-mediated LPL inhibition .
Therapeutic Insights
-
In Apoa5−/− mice, recombinant ApoA5 restored intravascular LPL levels and reduced triglycerides by 86% (from 1,116 to 87 mg/dL) .
-
An inhibitory ANGPTL3/8 antibody (IBA490) mimicked ApoA5’s function, normalizing triglyceride levels in mice .
Subcellular Localization
-
Double immunofluorescence with ApoA5 antibodies revealed that olanzapine-induced hypertriglyceridemia correlates with ApoA5 accumulation in lipid droplets rather than plasma membranes .
Implications for Metabolic Disease Research
ApoA5 antibodies are indispensable for:
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research suggests that apoA5 promotes hepatic TG storage and contributes to the development of non-alcoholic fatty liver disease. PMID: 25938357
- Studies demonstrate that apoA-V is secreted into bile, providing a potential route for delivery of hepatic apoA-V to the gut lumen. PMID: 26505974
- The increase in apolipoprotein A mRNA induced by rosiglitazone is not directly mediated by peroxisome proliferator-activated receptor gamma. PMID: 16570166
- ApoA-V exhibits inefficient trafficking within the secretory pathway, its intracellular itinerary can be regulated by changes in cellular TG accumulation, and apoA-V synthesis can modulate VLDL TG mobilization and secretion. PMID: 21115968
- Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. PMID: 20047745
- ApoA-V enhances insulin secretion in beta-cells and evidence suggests an internalization pathway involving midkine as a partner. PMID: 19910685
- The hypotriglyceridemic gene APOA5 is regulated by thyroid hormone. PMID: 15941710
- Data suggest that the absence of significant changes in Apoa5 gene expression during chronic fructose-induced triglyceride elevation excludes its major role in mechanisms compensating severe hypertriglyceridemia. PMID: 16238453
- Research indicates that the C terminus of apoA-V is essential for lipid droplet association in transfected hepatoma cells and lipoprotein association in conditioned medium, while the signal peptide is required for extracellular trafficking of this protein. PMID: 18450648
